

Press Release

India



Sanofi India Limited continues to deliver strong performance in insulin portfolio

Mumbai, April 28th, 2026. Sanofi India Limited (SIL) announced its financial results for the quarter ended on March 31, 2026.

In the **Domestic market**, the Insulin portfolio delivered exceptional performance for the second consecutive quarter, achieving **double-digit growth** versus last year and versus previous quarter, demonstrating **Sanofi's established equity in the Diabetes Injectable segment**.

Our strategic partnerships in Cardiovascular (CV), Oral anti Diabetes (OAD) and Central Nervous System (CNS) segments have established a robust foundation.

However, the overall results for this quarter have been impacted by transactions relating to partnership transitions.

Export sales are stabilizing, despite geopolitical situation.

The Company continues to drive significant efficiency improvements through targeted market initiatives, refined go-to-market strategies, and operational excellence programs.

Deepak Arora

Managing director

*"Despite current focus on newer diabetes therapies, our **14% registered growth** (vs previous quarter) and **19% registered growth** (vs last year) validates what clinical guidelines consistently affirm: **insulin remains essential for comprehensive diabetes care**. Our success across both public and private sectors reflects the medical community's continued trust in insulin as the **gold standard for reliable, predictable diabetes management** — a position that remains unshakeable regardless of market trends.*

Our strategic partnerships will catalyse growth, strengthen our commercial footprint, enhance market penetration, and create meaningful connections with healthcare professionals across therapeutic areas.

We remain committed to driving operational excellence while broadening access to both established and innovative therapies, throughout India."

Sanofi in India

Present in India for nearly seven decades, Sanofi has earned the trust of customers and stakeholders for its commitment to promoting health. As Sanofi chases the miracles of science to improve people's lives, it continues to engage across the entire health spectrum from prevention with vaccines to wellness, treatment, patient support & capacity building.

Sanofi's India Charitable Access Program (InCAP) is the country's longest running humanitarian program providing free treatment to people afflicted with Lysosomal Storage Disorders. Sanofi conducts clinical trials in India, so that the country can have quicker access to the latest from the company's global pipeline. Sanofi India's world-class manufacturing site in Goa produces for people in India and 24+ other countries. Sanofi has located one of its four global talent hubs

in Hyderabad, India, from where wide range of services are provided globally.

Recognized by the 'Top[®] Employers Institute' – a global authority that honours excellence in people practices since 2019, Sanofi's local entities include Sanofi India Limited (SIL - listed entity), and Sanofi Healthcare India Pvt. Ltd. (SHIPL).

For more information, visit: www.sanofi.com/en/in, [LinkedIn](#) and [Twitter](#).

Media Relations

Vinifer Gandhi | vinifer.gandhi@sanofi.com